Status:
COMPLETED
Methylphenidate for Ptsd and Stroke Veterans
Lead Sponsor:
VA Office of Research and Development
Conditions:
PTSD
Stroke
Eligibility:
All Genders
40-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Veterans with post-traumatic stress disorder (PTSD) have an increased risk of developing ischemic stroke. Veterans enduring PTSD face difficulties in managing their PTSD severity after suffering from ...
Detailed Description
Veterans with post-traumatic stress disorder (PTSD) have an increased risk of developing ischemic stroke. Veterans enduring PTSD face difficulties in managing their PTSD severity after suffering from ...
Eligibility Criteria
Inclusion
- Male or female Veteran of US military; signed informed consent
- Criterion A Index Trauma(s) resulting in PTSD occurred during adulthood prior to stroke
- CAPS-5 past week total score =23 at baseline visit
- Willing to refrain from antipsychotics, mood stabilizers, stimulants, and any formulation of MPH
- First-ever symptomatic ischemic stroke radiologically verified, occurring within past 1-12 months
- Females of child-bearing potential (i.e. not postmenopausal or surgically sterile) must be using a medically acceptable method of birth control and should not be pregnant nor have plans for pregnancy or breastfeeding during the study
Exclusion
- Moderate to severe cognitive impairment (Montreal Cognitive Assessment score \<16/30)
- Poor pre-stroke baseline function of a modified Rankin score \>2
- Presence of any standard MRI contraindications
- Current diagnosis of DSM-5-defined bipolar disorder I, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or major depressive disorder with psychotic features (MINI)
- Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months
- Patients who utilize alcohol or cannabis but do not meet criteria for moderate or severe disorder are permitted at the discretion of the investigator
- Participants must agree to abstain from illicit drugs during the study
- Increased risk of suicide that necessitates inpatient treatment or warrants additional therapy excluded by the protocol; and/or intensity of suicidal ideation (Type 4 or Type 5) or any suicidal behavior in the past 3 months on Columbia Suicide Severity Rating Scale (C-SSRS)
- Use of any investigational drug, MPH formulation, antipsychotics, mood stabilizers, monoamine oxidase inhibitors, stimulants or any medication known to be a potent (strong) cytochrome P450 subtype 3A4 inhibitor within 2 weeks of baseline
- Treatment with evidence-based trauma-focused therapy for PTSD within two weeks of baseline (if participant is receiving therapy, he/she must complete treatment prior to entering study)
- Supportive psychotherapy in process at time of Screening may be continued during the study.
- History of moderate or severe TBI as defined by the Ohio State University TBI Identification Method
- Based on investigator's clinical judgment, history of mild TBI is not excluded
- Any clinically significant, uncontrolled, or medical/surgical condition or laboratory abnormality that would contraindicate use of MPH (see Human Subjects section)
- Severe allergic reaction, bronchospasm, or hypersensitivity to any MPH formulation.
- Litigating for compensation for a psychiatric disorder. Veterans who are in the process of applying for or receiving VA service-connected disability are eligible
- Current enrollment in another intervention trial for PTSD or stroke
- Persons imprisoned, diagnosed with terminal illness, or require surrogate for consent
Key Trial Info
Start Date :
January 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 5 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04885257
Start Date
January 14 2022
End Date
May 5 2025
Last Update
June 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham VA Medical Center, Birmingham, AL
Birmingham, Alabama, United States, 35233-1927